These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 27993425)
1. Serum Testosterone Levels in Early Prediction of Prostate Cancer Risk. Bentmar Holgersson M; Malm J; Lundberg Giwercman Y Eur Urol; 2017 Jun; 71(6):992-994. PubMed ID: 27993425 [No Abstract] [Full Text] [Related]
2. Both High and Low Serum Total Testosterone Levels Indicate Poor Prognosis in Patients with Prostate Cancer. Izumi K; Shigehara K; Nohara T; Narimoto K; Kadono Y; Mizokami A Anticancer Res; 2017 Oct; 37(10):5559-5564. PubMed ID: 28982870 [TBL] [Abstract][Full Text] [Related]
3. A case control study of sarcosine as an early prostate cancer detection biomarker. Ankerst DP; Liss M; Zapata D; Hoefler J; Thompson IM; Leach RJ BMC Urol; 2015 Oct; 15():99. PubMed ID: 26429735 [TBL] [Abstract][Full Text] [Related]
4. Low Serum Testosterone But Not Obesity Predicts High Gleason Score at Biopsy Diagnosed as Prostate Cancer in Patients with Serum PSA Lower than 20 ng/ml. Shiota M; Takeuchi A; Sugimoto M; Dejima T; Kashiwagi E; Kiyoshima K; Inokuchi J; Tatsugami K; Yokomizo A Anticancer Res; 2015 Nov; 35(11):6137-45. PubMed ID: 26504040 [TBL] [Abstract][Full Text] [Related]
5. Serum testosterone as a biomarker for second prostatic biopsy in men with negative first biopsy for prostatic cancer and PSA>4ng/mL, or with PIN biopsy result. Fiamegos A; Varkarakis J; Kontraros M; Karagiannis A; Chrisofos M; Barbalias D; Deliveliotis C Int Braz J Urol; 2016; 42(5):925-931. PubMed ID: 27532110 [TBL] [Abstract][Full Text] [Related]
6. [2014 Annual Meeting of the American Urological Association: early screening and molecular markers of prostate cancer]. Tao T; Guan H; Chen M Zhonghua Nan Ke Xue; 2015 Jun; 21(6):555-60. PubMed ID: 26242049 [TBL] [Abstract][Full Text] [Related]
7. Plasma levels of E-cadherin and MMP-13 in prostate cancer patients: correlation with PSA, testosterone and pathological parameters. Bonaldi CM; Azzalis LA; Junqueira VB; de Oliveira CG; Vilas Boas VA; Gáscon TM; Gehrke FS; Kuniyoshi RK; Alves BC; Fonseca FL Tumori; 2015; 101(2):185-8. PubMed ID: 25733385 [TBL] [Abstract][Full Text] [Related]
8. Testosterone as a prospective predictor of pathological Gleason score and pathological stage in prostate cancer. Drobková H; Jurečeková J; Grendár M; Kliment J; Halašová E; Kliment J Gen Physiol Biophys; 2017 Dec; 36(5):549-556. PubMed ID: 29372688 [TBL] [Abstract][Full Text] [Related]
9. [Current results on PSA-based prostate cancer detection]. Graefen M; Schlomm T; Steuber T; Sauter G Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2014 Mar; 57(3):312-7. PubMed ID: 24562706 [TBL] [Abstract][Full Text] [Related]
10. [PSA 2010--the beginning of a new era in early detection of prostate cancer]. Börgermann C; Sieverding M; Fornara P; Graefen M; Hammerer P; Semjonow A; Schröder F; Rübben H Urologe A; 2006 Sep; 45 Suppl 4():127-33. PubMed ID: 16941115 [No Abstract] [Full Text] [Related]
11. Prostate-specific antigen, risk factors, and prostate cancer: confounders nestled in an enigma. Thompson IM; Ankerst DP; Tangen CM J Natl Cancer Inst; 2010 Sep; 102(17):1299-301. PubMed ID: 20724727 [No Abstract] [Full Text] [Related]
14. Predictive role of free prostate-specific antigen in a prospective active surveillance program (PRIAS). Vasarainen H; Salman J; Salminen H; Valdagni R; Pickles T; Bangma C; Roobol MJ; Rannikko A World J Urol; 2015 Nov; 33(11):1735-40. PubMed ID: 25822705 [TBL] [Abstract][Full Text] [Related]
15. The role of serum testosterone to prostate-specific antigen ratio as a predictor of prostate cancer risk. Gurbuz C; Canat L; Atis G; Guner B; Caskurlu T Kaohsiung J Med Sci; 2012 Dec; 28(12):649-53. PubMed ID: 23217356 [TBL] [Abstract][Full Text] [Related]
16. Nadir Testosterone after Long-Term Followup Predicts Prognosis in Patients with Prostate Cancer Treated with Combined Androgen Blockade. Kamada S; Sakamoto S; Ando K; Muroi A; Fuse M; Kawamura K; Imamoto T; Suzuki H; Nagata M; Nihei N; Akakura K; Ichikawa T J Urol; 2015 Nov; 194(5):1264-70. PubMed ID: 25861958 [TBL] [Abstract][Full Text] [Related]
17. [New challenges and earlier approved methods in the laboratory diagnosis of prostate cancer]. Kovács GL Magy Onkol; 2014 Dec; 58(4):301-9. PubMed ID: 25517448 [TBL] [Abstract][Full Text] [Related]
18. Higher sex hormone-binding globulin and lower bioavailable testosterone are related to prostate cancer detection on prostate biopsy. García-Cruz E; Carrión Puig A; García-Larrosa A; Sallent A; Castañeda-Argáiz R; Piqueras M; Ribal MJ; Leibar-Tamayo A; Romero-Otero J; Alcaraz A Scand J Urol; 2013 Aug; 47(4):282-9. PubMed ID: 23181478 [TBL] [Abstract][Full Text] [Related]
19. High-grade prostate cancer is associated with low serum testosterone levels. Schatzl G; Madersbacher S; Thurridl T; Waldmüller J; Kramer G; Haitel A; Marberger M Prostate; 2001 Apr; 47(1):52-8. PubMed ID: 11304729 [TBL] [Abstract][Full Text] [Related]
20. Serum sex steroid hormone levels and polymorphisms of CYP17 and SRD5A2: implication for prostate cancer risk. Kakinuma H; Tsuchiya N; Habuchi T; Ohyama C; Matsuura S; Wang L; Nakamura A; Kato T Prostate Cancer Prostatic Dis; 2004; 7(4):333-7. PubMed ID: 15477877 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]